Patents by Inventor Donald Waldron

Donald Waldron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB
    Publication number: 20140142101
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Application
    Filed: October 14, 2013
    Publication date: May 22, 2014
    Applicants: Radiation Therapy Oncology Group of the Americal College of Radiology, HistoRx, Inc.
    Inventors: Arnab CHAKRAVARTI, Robert Pinard, Donald Waldron, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro
  • CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB
    Publication number: 20100144540
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Application
    Filed: September 22, 2009
    Publication date: June 10, 2010
    Inventors: Arnab Chakravarti, Robert Pinard, Donald Waldron, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro, Alpana Waldron